Ghana Grants First Medical Cannabis Cultivation Licenses to Two Firms

First Licenses Issued Under 2020 Framework

NACOC issued two cultivation licenses on July 31, 2026—the first under Ghana's medical cannabis program authorized by Act 1019. The commission didn't disclose the names of the licensees, facility locations, or projected cultivation capacity in its announcement. Act 1019, passed in December 2020, legalized cannabis cultivation, processing, and distribution for medical and industrial purposes while maintaining criminal penalties for recreational use.

Regulatory Timeline Since 2020

Ghana's medical cannabis framework took nearly six years to move from statute to operational licensing. Parliament enacted Act 1019 on December 22, 2020. NACOC published draft cultivation regulations in March 2022 but didn't finalize them until late 2024. The commission opened its first application window in January 2025. This timeline mirrors delays seen in other African medical programs, including Lesotho and Zimbabwe, where regulatory infrastructure lagged statutory authorization by three to five years.

Application Requirements and Compliance Burden

Applicants faced stringent security, agronomic, and financial-disclosure requirements under NACOC's licensing framework. According to the 2024 final regulations, applicants must demonstrate secure perimeter fencing, video surveillance covering all cultivation zones, and a seed-to-sale tracking system compatible with NACOC's central database. Minimum capital requirements were set at 500,000 Ghanaian cedis (approximately $31,000 USD at July 2026 exchange rates). Applicants must also submit criminal background checks for all directors and a detailed cultivation plan specifying cannabinoid targets and testing protocols.

Export Market Ambitions

Ghana's program explicitly permits export to jurisdictions with legal medical cannabis markets. This positions the country to compete with Lesotho and South Africa for European pharmaceutical contracts. Act 1019 authorizes NACOC to issue export permits for dried flower, oils, and isolates meeting EU-GMP standards. Lesotho, which launched cultivation licensing in 2018, exported approximately 12 metric tons of medical cannabis to Europe in 2025, according to trade data from the Lesotho Ministry of Trade. Ghana's equatorial climate and lower labor costs relative to South Africa may offer competitive advantages, though infrastructure gaps in cold-chain logistics remain a constraint.

The two licenses represent a test case for whether Ghana's regulatory apparatus can support a functional supply chain from cultivation through export certification.

Domestic Medical Access Provisions

Act 1019 permits domestic dispensing of cannabis-based medicines through licensed pharmacies, but NACOC hasn't yet issued pharmacy or physician-prescriber licenses. The statute allows physicians to prescribe cannabis for conditions including chronic pain, epilepsy, and chemotherapy-induced nausea. NACOC's 2024 regulations require pharmacies to obtain a separate dispensing license and maintain a controlled-substance registry. No pharmacy applications have been approved as of July 31, 2026. Cultivated product will initially target export markets exclusively.

Enforcement and Illicit-Market Context

Ghana remains a transit hub for illicit cannabis moving from West Africa to European markets, complicating enforcement of the legal medical framework. NACOC reported seizing 14.3 metric tons of cannabis in 2025, primarily in the Volta and Eastern regions. The commission hasn't detailed how it will distinguish legal cultivation from diversion or how it will monitor compliance with cultivation caps. Act 1019 imposes penalties of up to 15 years' imprisonment for unlicensed cultivation or diversion of licensed product to recreational markets.

What Comes Next

NACOC's next licensing round and the issuance of processing and export permits will determine whether Ghana's program can scale beyond two pilot operators. The commission hasn't announced a timeline for additional cultivation licenses or for processor and distributor applications. For full background on Ghana's medical cannabis regulatory development, see the CannIntel topic hub on Ghana Medical Cannabis Program. Industry observers will be watching whether NACOC publishes the names and facility details of the two licensees—a transparency measure common in mature medical markets but inconsistent across African jurisdictions.